A new highly sensitive targeted imaging method for early tumor detection

一种用于早期肿瘤检测的新型高灵敏度靶向成像方法

• 批准号: 10651258
• 负责人: AURELIAN RADU
• 金额: $ 25.82万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-08 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10651258
• 关键词: Affinity; Anatomy; Antibodies; Binding; Blood; Blood Vessels; Brain; Cancer Diagnostics; Cell Culture Techniques; Cells; Circulation; Clinical; Clinical Research; Complex; Coupled; Data; Detection; Development; Diameter; Early Diagnosis; Elements; Excision; Fc Receptor; Follicle Stimulating Hormone Receptor; Future; General Population; Hormones; Human; Image; Imaging Techniques; Immunoglobulin G; Immunohistochemistry; Implant; Incentives; Injections; Label; Life Style; Ligands; Location; Magnetic Resonance Imaging; Magnetism; Malignant Neoplasms; Medical center; Methods; Modeling; Modification; Monoclonal Antibodies; Mus; Neoplasm Metastasis; Neoplasms in Vascular Tissue; Nutraceutical; Organ; Patients; Performance; Periodicals; Pharmaceutical Preparations; Pilot Projects; Preparation; Procedures; Publishing; Reporting; Reticuloendothelial System; Risk; Screening for cancer; Signal Transduction; Surface; Syndrome; System; Technology; Testing; Tissues; Translations; Tumor Cell Line; Tumor Markers; Visualization; Work; anticancer research; bone; cancer clinical trial; cancer imaging; cancer predisposition; cancer therapy; cancer type; clinical translation; cost; detection sensitivity; high risk; imaging agent; imaging detection; imaging modality; intravenous injection; iron oxide; mortality; neoplastic cell; particle; patient screening; patient subsets; performance tests; pre-clinical; programs; targeted imaging; tumor; tumor DNA; tumor xenograft

SUMMARY The project is aimed at the development of a new highly sensitive multi-tumor type imaging procedure. The imaging is based on a marker of the tumor blood vessels, the Follicle Stimulating Hormone Receptor (FSHR), which was shown by us to be present in all major cancer types and at all stages, advanced and incipient. The first Aim is to assemble the imaging agents and to test them in cell cultures. Anti-FSHR antibodies will be labeled with imaging agents, tested for binding to cells in culture that produce FSHR and will be optimized by selecting the best antibodies. The second Aim is to test the performance of the imaging agents in mice. The imaging agents will be delivered by intravenous injection in mice that carry tumors formed by implanting human tumor cells and the tumors will be imaged. A tumor cell line that generate metastatic lesions in mice will be used to determine the smallest tumor size that can be detected. Tumors will be analyzed in parallel by immunohistochemistry in tissue sections, in order to determine the yield and sensitivity of detection by imaging. The procedure can contribute to a national priority in cancer research – to reduce substantially cancer mortality by early detection of asymptomatic tumors. Early detection increases substantially the chance of successful therapy, and significantly reduces the overall cost of cancer treatment. The method could be initially tested for periodic screening of patients who are at high risk of developing cancer.

概括 该项目旨在开发一种新的高灵敏度多肿瘤型成像程序。这 成像基于肿瘤血管的标记物——卵泡刺激激素受体（FSHR）， 我们发现它存在于所有主要癌症类型和所有阶段（晚期和初期）中。这 第一个目标是组装显像剂并在细胞培养物中测试它们。抗 FSHR 抗体将被标记 与显像剂一起，测试与培养中产生 FSHR 的细胞的结合，并将通过选择进行优化 最好的抗体。第二个目标是测试显像剂在小鼠体内的性能。成像 药物将通过静脉注射的方式输送到携带植入人类肿瘤形成的肿瘤的小鼠体内 细胞和肿瘤将被成像。在小鼠体内产生转移性病变的肿瘤细胞系将被用于 确定可检测到的最小肿瘤大小。肿瘤将被并行分析 组织切片中的免疫组织化学，以确定成像检测的产量和灵敏度。 该程序可以促进国家癌症研究的优先事项——大幅降低癌症死亡率 通过早期发现无症状肿瘤。早期发现大大增加了成功的机会 治疗，并显着降低癌症治疗的总体成本。该方法可以初步测试 定期筛查患有癌症高风险的患者。